Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease

Inclusion Criteria: * Diagnosis of CD (involving small intestine and/or colon), confirmed by both endoscopy and histopathology at least 3 months prior to Visit 1 * Previous use of any type of corticosteroids or immunosuppressants for the treatment of CD * Moderate to severe active CD defined by a CDAI score of ≥220 to ≤450 points at Visit 1 Exclusion Criteria: * Diagnosis of ulcerative colitis, indeterminate colitis, pseudomembranous colitis or coeliac disease * Enterocutaneous, abdominal or pelvic active fistulae, abscesses or fistulae likely to require surgery during the study * GI surgery (including appendectomy) within 12 weeks prior to Visit 2 (Baseline) or has surgery planned or deemed likely to require surgery for CD during the study